Rules of the road

Investigators and companies have long been devising strategies to mitigate or preempt toxicities from CAR T cell therapies without compromising efficacy. Now, data presented at the American Society of Hematology meeting suggest strategies to prevent or reduce cytokine release syndrome are on the right track, and could even be taken further.

More work needs to be done to understand the causes of and solutions for neurological toxicities, especially in light of reports of cerebral edema in trials of Juno Therapeutics Inc.’s JCAR015...